Erratum to: Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: Results from the multicentre, randomised, double-blind, active-controlled HARMONY II study (Journal of Obstetrics and Gynaecology, (2013), 33, 6, (591–596), 10.3109/01443615.2013.800851);Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: Results from the multicentre, randomised, double-blind, active-controlled HARMONY II study

Journal of Obstetrics and Gynaecology

Volumn 33, Issue 6, 2013, Pages 591-596

  Macias G ^a   Merki Feld, G S ^b   Parke, S ^c   Mellinger, U ^c   Serrani, M ^c  

^a Mexican Navy Research Institute   (Mexico)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c BAYER PHARMA AG   (Germany)

Author keywords

Dienogest; HARMONY II; Headache; Hormone withdrawal associated symptoms; Oestradiol valerate; Oral contraception

Indexed keywords

DIENOGEST PLUS ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN;

ADULT; ARTICLE; BLOATING; BREAST TENDERNESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PAIN ASSESSMENT; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPOTTING; SWELLING; VISUAL ANALOG SCALE; VOMITING;

ADULT; CONTRACEPTIVES, ORAL, COMBINED; DOUBLE-BLIND METHOD; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; HEADACHE; HUMANS; LEVONORGESTREL; NANDROLONE; PELVIC PAIN; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 84881269240     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.1080/01443615.2016.1191220     Document Type: Erratum

References (21)

1. Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D. 2009. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: A seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 80: 436-444.
2. Allais G, Castagnoli Gabellari I, De Lorenzo C, Mana O, Benedetto C. 2011. Oral contraceptives in migraine therapy. Neurological Sciences 32(Suppl 1): S135-S139.
3. Allais G, Gabellari IC, Airola G, Borgogno P, Schiapparelli P, Benedetto C. 2009. Headache induced by the use of combined oral contraceptives. Neurological Sciences 30(Suppl 1): S15-S7.
4. Bayer HealthCare Pharmaceuticals. 2008. First cleared for market launch in estradiol-based oral contraceptive Qlaira Europe. Available at: Www.investor.bayer.de/en/news/archive/investor-news-2008/investor-news/ showNewsItem/1008/1235464620/14ac57ccfd (Accessed 5 July 2012).
5. Bayer HealthCare Pharmaceuticals. 2010. US FDA approves, a new oral contraceptive for the prevention of pregnancy. Available Natazia at: Http://pharma.bayer.com/scripts/pages/en/news-room/news-room/news-room91.php (Accessed 5 July 2012).
6. Endicott J, Nee J, Harrison W, Blumenthal R. 1993. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacology Bulletin 29: 321-326.
7. European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Proprietary Medicinal Products (CPMP). 2002. Note for guidance on clinical investigation of medicinal products for treatment of nociceptive pain. Available at: Www.tga.gov.au/pdf/euguide/ewp061200 fi nal.pdf (Accessed 5 July 2012).
8. Headache Classifi cation Subcommittee of the International Headache Society. 2004. The International Classifi cation of Headache Disorders, 2nd edn. Cephalalgia 24(Suppl 1): 9-160.
9. Jensen JT, Parke S, Mellinger U, Serrani M, Mabey RG Jr. 2013. Hormone withdrawal-associated symptoms: Comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate. European Journal of Contraception and Reproductive Health Care: Epub ahead of print May 2.
10. Klipping C, Duijkers I, Trummer D, Marr J. 2008. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 78: 16-25.
11. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. 2006. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67: 2154-2158.
12. Martelletti P, Farinelli I, Coloprisco G, Patacchioli FR. 2007. Role of NSAIDs in the acute treatment of headache. Drug Development Research 68: 276-281.
13. Rosenberg MJ, Waugh MS, Meehan TE. 1995. Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation. Contraception 51: 283-288.
14. Rosenberg MJ, Waugh MS. 1998. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. American Journal of Obstetrics and Gynecology 179: 577-582.
15. Silberstein SD. 2001. Headache and female hormones: What you need to know. Current Opinion in Neurology 14: 323-333.
16. Spona J, Elstein M, Feichtinger W et al. 1996. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54: 71-77.
17. Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ. 1997. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstetrics and Gynecology 89: 179-183.
18. Sulak P, Willis S, Kuehl T, Coff ee A, Clark J. 2007. Headaches and oral contraceptives: Impact of eliminating the standard 7-Day placebo interval. Headache 47: 27-37.
19. Sulak PJ, Kaunitz AM, London AM, Moore AM, Nelson AL. 2007. Extended regimen oral contraceptives-practical management. Journal of Family Practice 56: S1-S8.
20. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. 2000. Hormone withdrawal symptoms in oral contraceptive users. Obstetrics and Gynecology 95: 261-266.
21. Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. 2009. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. European Journal of Contraception and Reproductive Health Care 14: 221-232.